Technohal
Guest staff

prof.dr. W.H. van Harten (Wim)

Professor Quality Management and Health Care Technology
BMS-TPS-HTSR
Technohal 3105
w.h.vanharten@utwente.nl
+31534894429
Business card

Wim H. van Harten graduated as M.D. and specialized in tropical medicine. On returning from Africa he focused on public health and health administration. He obtained a degree in community medicine/public and worked Chief Medical Advisor of a major health insurance company (1986-1992). Thereafter worked  as CEO at t the rehabilitation hospital “Het Roessingh” in Enschede and as member of the Executive Board of the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL). I Since 2015 he is CEO at Rijnstate Hospital Arnhem. From 2005 onwards  he was  appointed as Research Group leader at the Division of Psychosocial Research and Epidemiology at the NKI.

 

Since 2001 he is part-time professor on “Quality Management and Health Care Technology” at the department of Health Technology and Services Research of the School of Management and Governance. So far, he supervised over 20 Ph.D graduations and presently his group consists of 1 postdoc and 5 PhD students in the NKI and 5 in other universities. He published over 200 peer reviewed papers on health services and quality management, especially  Health Technology Assessment, E-health and Process improvement.

 

He served as President of the OECI from 2011-2014, presently as Chair OECI Working Group on Health Economics and member of the OECI Cancer Center Accreditation and Designation Board. From 2008 – 2014 he served as Board member of the Netherlands Hospital Association with the portfolio of innovation, drug costs and quality issues.

 

From 2015 he is CEO of Rijnstate (general) Hospital in Arnhem, a large teaching hospital with an annual expenditure of € 600 million and around 5500 employees, of whom around 300 medical specialists and 110 MDs in specialist training. He is Chair of mProve, a collaborative of 7 large teaching hospitals in the Netherlands with a total annual expenditure of ± € 4 billion.  

Expertise

  • Medicine and Dentistry

    • Patient
    • Health Care Cost
    • Cost-Effectiveness Analysis
    • Malignant Neoplasm
    • Breast Cancer
    • Hospital
    • Therapeutic Procedure
    • Technology Assessment

Organisations

Publications

2025

Accessibility to cancer medicines in Europe: Towards equitable access and fair pricing (2025)[Thesis › PhD Thesis - Research UT, graduation UT]. University of Twente. Vancoppenolle, J. M. J.https://doi.org/10.3990/1.9789036565806Device based monitoring in digital care and its impact on hospital service use (2025)npj Digital Medicine, 8(1). Article 16 (E-pub ahead of print/First online). Jansen, A. J. S., Peters, G. M., Kooij, L., Doggen, C. J. M. & van Harten, W. H.https://doi.org/10.1038/s41746-024-01427-8

2024

DNA sequencing in oncology: a focus group study on a duty to recontact (2024)Future Science OA, 10(1). Article 2432233. Giesbertz, N. A. A., Assen, L. S., van Harten, W. H. & Bredenoord, A. L.https://doi.org/10.1080/20565623.2024.2432233Long-term quality of life in patients with bladder cancer following radical cystectomy (2024)BJU International (E-pub ahead of print/First online). Akdemir, E., Stuiver, M. M., van de Kamp, M. W., der Hulst, J. B. v., Mertens, L. S., Hendricksen, K., van Harten, W. H., May, A. M. & Sweegers, M. G.https://doi.org/10.1111/bju.16610Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives (2024)BMC cancer, 24(1). Article 1441. van Schaik, L. F., Engelhardt, E. G., van Harten, W. H. & Retèl, V. P.https://doi.org/10.1186/s12885-024-13167-9Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review (2024)Critical Reviews in Oncology/Hematology, 202. Article 104441. van Schaik, L. F., Engelhardt, E. G., Wilthagen, E. A., Steeghs, N., Fernández Coves, A., Joore, M. A., van Harten, W. H. & Retèl, V. P.https://doi.org/10.1016/j.critrevonc.2024.104441Moderators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis (2024)Journal of cancer survivorship, 18, 1492-1503. Hiensch, A. E., Beckhaus, J., Witlox, L., Monninkhof, E. M., Schagen, S. B., van Vulpen, J. K., Sweegers, M. G., Newton, R. U., Aaronson, N. K., Galvão, D. A., Steindorf, K., Stuiver, M. M., Mesters, I., Knoop, H., Goedendorp, M. M., Bohus, M., Thorsen, L., Schulz, K. H., Schmidt, M. E., … May, A. M.https://doi.org/10.1007/s11764-023-01392-3High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers (2024)Acta oncologica, 63, 701-709. Verbeek, J. G. E., Azarang, L., Pilli, L. E., De Jong, V. M. T., Jager, A., Linn, S. C., Retèl, V. P. & Van Harten, W. H.https://doi.org/10.2340/1651-226X.2024.40276Organizing Virtual Care, Digital Services Replacing Hospital In-Care and Outpatient Care (2024)Mayo Clinic Proceedings: Digital Health, 2(3), 405-410. van Harten, W., Doggen, C. & Kooij, L.https://doi.org/10.1016/j.mcpdig.2024.06.007Technological Aspects of Device-Based Monitoring and the Impact on Hospital Services (2024)Studies in health technology and informatics, 316, 176-177. Jansen, A. J., Peters, G., Kooij, L., Doggen, C. & van Harten, W.https://doi.org/10.3233/SHTI240372

Research profiles

Courses academic year 2025/2026

Courses in the current academic year are added at the moment they are finalised in the Osiris system. Therefore it is possible that the list is not yet complete for the whole academic year.

Courses academic year 2024/2025

Courses academic year 2023/2024

Address

University of Twente

Technohal (building no. 18), room 3105
Hallenweg 5
7522 NH Enschede
Netherlands

Navigate to location

Organisations

Scan the QR code or
Download vCard